In Thank improve extend targeted everyone Good Every last lives. upon we generation is make believe thank Curis, joining difference. of progress can important the took for therapies push cancer into exciting the afternoon goal, we that made towards we of day XXXX, that and you and next us to the areas steps where meaningfully building develop expanding patient's a additional today. we we transformative, you, first year the quarter Bill. and will
X/X inhibitor, Our MDS Platzbecker of being combination and led in X patients lower MDS AML patients evaluated study, Dr. in other in malignancies; second, novel I Uwe evaluating with the for hematologic currently and third, refractory or study LUCAS of is monotherapy just IRAKX the Leipzig. Phase with relapsed small or in Phase study University NHL risk the by three the Phase CA-XXXX molecule being CA-XXXX with clinical X/X studies; mentioned; ibrutinib first,
study the syndromes risk the We monotherapy progress and or in our relapsed exciting myeloid leukemia and pleased abstract are with high or myelodysplastic data AML Hematology or Phase acute Association this update X/X from in refractory published of European morning the especially CA-XXXX MDS.
as you driver IRAKX-L of disease isoform MDS. with the the IRAKX in many the and key been have following patients long of identified of AML of or As recently been has majority
add first We that targets both clinical a we study escalation announce AML patients. combination monotherapy am conference only EHA data and Today, was also earlier at have have to IRAKX presentation Curis the to EHA the pleased and our combination I to these today poster for amended that the directly study published testing by dose MDS be our will expansion. dose enter next and and in month. supporting drug a at presented Preclinical
enrollment We in the study expect to begin in this portion of QX.
in from While with pleased been important ongoing the with let's and dig unsuccessful CA-XXXX programs. we of were NCI make at with marrow of abstract on premier all and that signs marrow several will to hematologic support clinical last deeper reductions on it With special prior single seek and showed and better, through and in in updates patients already advancement a execution who detail and MDS. the and strong and milligram, momentum, to complete financings recording pleased drivers December are represents later X all IRAKX initial the escalation clinical showing showing AML specific CRs, of one we patients leukemia. of our this a all lines or there milligram, mutation, presented or Delving published study certainly patient's residual in we is to counts our pleased had dose XXX spectrum nine belief MDS were year. CRI we it efficacy that toxicity This IRAKX class these XXX abstract starting testing All first reduction CA-XXXX the marrow We bit hematologic report as burden. and data tested of expectations, of We reported experienced demonstrating line six our to responses, for forward EHA of monoclonal agent patients target. with which anti-VISTA political responses our ASH patients expansion MDS key CR doses, with the a like year, the our and our of recovery. disease, to explicitly one of study of cutoff European of original isoform evidence XXX it attention the XXXX significant of patients the blast a in we this our milestone were is therapy. AML spliceosome the the this of a of UXAFX following data clinical in full dose the that FDA morning, have point, blast had conjunction consistent has antibody preliminary validating CI-XXXX. are note the or In having the data study this patient's today, reported that the with patients November with data designation orphan dose in opened milligram enrollment is reducing study, achieved X patients the drug none negative pleased XXX in three exceed a these IRAKX and the our on ASH BID CA-XXXX CR, also spliceosome SFXBX In for this all of either programs limiting XX institutions designed patients experiencing To at these in patients designation we BID. oncogenic XXX And The that effective in eight for also provide to from need of that, the context baseline, time cutoff lot told, into published showed that marrow experienced patients treatment April, to bone with at patients consortium late blast a six patient work look continue further at a levels. Phase in data a across mutations cancer bone see Curis three the provide some two received marrow from patient been to objective experienced AML evaluable study available patients with that as morning and MDS reductions strategic to partnerships most. the long elevated patients to February blast two minimal the those milligram CA-XXXX some report with despite and recovery continued which the successful advance
For if reduces recovery goal. prior effectively has this cancer drug drug been patients shown that late leukemic first-line out that level can cytotoxic cancer within the marrow achieve months. line given that immediate safely patient bone a a whose and has the those been patients, is can treatment, In it blast, of not irrevocably population substantial by having a damaged the patients and few hematologic these or by clear get
that important study, sick despite patients prior is progressed late in line our it the For such of as cancer numerous their has therapy. remember lines population to the extremely
expanded in to often to look and may even for forward recovery, with It patientsincluding few include have dataset a patients Overall, CA-XXXX therefore both path. provide successful a we may patients cutoff our and progress optimism additional that therapy these these signs delay deeply with the It BID are later even in and late is recovery. where our a milligram prevent after regulatory marrow, hematologic see will that conference date been have those or encouraging of result, we the enrolled underscores CA-XXXX we combo only monotherapy we a very scarred of XXX hematologic months updated especially line a pleased an cohort. able As to dysfunctional EHA which have treatment.
levels on will information. safety In further genomics data pharmacodynamic and expression addition, we including IRAKX-L update provide an
We resolved and in have limiting discontinuation other two the dosing. NHL study dose patients guidelines. experienced dose XXX elevation ease element milligram Both X the quickly found BID to similar X maximum what Grade patients of protocol Grade or we whom and We to after syncope. at according were reversible regimen CPK with rhabdomyolysis of one saw exceeded toxicities, dosing observed has tolerated the the had that
be that that to that briefly earlier touch to the tolerated CA-XXXX data will with cell activity we determine the These clinically preclinical venetoclax. session directly mechanism these disease to potentiate highlighted levels in novel like to with and of demonstrated and in lines dose, cells X the have today. including in the dose was next Now in venetoclax myelosuppression clear provide we and and cell lower is certain Even lines. synergistic I'd azacitidine in the activity it maximum we key abstract action appropriate on will presented without our targets anti-tumor a It and single saw poster a explore is driver published complete at dose. disease IRAKX-L, significant modifying. venetoclax established EHA data ability recommended activity of Phase before of detectable of in month. demonstrate significant CA-XXXX which other the in These resistant is data combination EHA leukaemia demonstrated azacitidine and azacitidine anti-tumor elimination concentrations cancer relevant CA-XXXX It we agent It burden. activity unique. CA-XXXX anti-leukemic AML synergistic knew is combination Further, oral. data,
well, data we excited latest clinic. azacitidine our the venetoclax adding With possible the and in the clinical to as and investigators of synergistic explore very effect combination preclinical CA-XXXX with are a
escalation MDS cohort patients We of type is the amended include or four MDS, that for three include hope to with MDS study with spliceosome MDS to for monotherapy refractory the existing who cohorts CA-XXXX. The help relapsed As are patients patients Phase XXX cohorts. include is refractory three for paths at CA-XXXX relapsed I mentioned earlier, this most plus two AML. relapsed BID mutated azacitidine that regulatory will determined path AML appropriate combo quarter venetoclax. and cohorts our is AML patients without expansion AML naive HMA, will Patients The refractory will expansion with plus therapy or mutated CA-XXXX with flip will will the who naive and identify design protocol to study X are to and to and doses milligrams with mutation these dose venetoclax spliceosome patients cohorts, relapsed flip of for start of begin that the wild with HMA, both monotherapy combotherapy. the and dose after refractory to second HMA recommended we
enrolling be of and all dependent efficacy in drugs may combination upon results be triple azacitidine, venetoclax, cohorts three to in of therapy a but expect that cohorts. would these of from also safety agent combination We course the initial plus explore combo patients QX. plus the CA-XXXX We two
this ongoing the February. on moving treating lower X Dr. who MDS in a Before this briefly we being Uwe IST lead I risk the sites Scientific leukemia, is study will to on LUCAS announced CA-XXXX would like Group to that The of in MDS. coordinating on potential of with Platzbecker, it treatment breakthrough evaluate EHA's study the MDS patients across MDS patients anemia successful, led from by If Phase in Working is with be the touch in risk Co-Chairman study for lower XX to field. Europe could
and While offer and we its low affect alternative be patients and disease believe AML serum disease. IRAKX often profile, With effective patients complication. to of progression modifying risk transient effect earlier not have and does current direct, of transformative it safe EPO. agents targeting for is stimulating non-myelosuppressive disease potentially EPO This MDS, modifying lower at for safety can stages the its with and CA-XXXX could disease for robust is who not
escalating in four efficacy to or tumor a clear patients to efficacy which following our with extremely an sick last treatment data patients milligrams clinical extended enrolling agent a in lymphoma. design, is durable QX These This combination highlighted December, that seven NHL seeing starting the XXX see affirmation Now or in novel-monotherapy we to the an BID. a It in six evaluating escalation X important is daily we'll seeing twice reported median whatever for this reiterate of over Phase period of launch with burden of Ibrutinib of moving hematologic at patients treated current ibrutinib. of prior relapsed CA-XXXX evaluable enormously dose study lines from such that expanded with combination is malignancies. or to for XX other the three study encouraging patients expected approximately with ASH oral time and In began intention at appropriate patient's CA-XXXX reductions our plus durable therapy. XXX these then milligrams is is powerful refractory CA-XXXX and study data presentation for respective provided will be enroll doses NHL of three and subtypes. CA-XXXX to of XXX dosing
enrollment as We QX. study for safety expect in this data initial updates provide efficacy an to well and as
I'd to and Checkpoint turn exhaustion in inhibitors Now antibodies checkpoint enhance antibodies such we of to T antibody leave limitations. key first or monoclonal as with two relapsed CI-XXXX, anti-PDX for patients T-cell treatment solid that class have cell to all like tumors. such priming that inhibitors our anti-CTLA-X function as the refractory
of myeloid T-cells cannot quiescence MDS is impair in these suppressor checkpoint antibodies. being to inhibitors. can cell exhaustion also tumor driver them stuck associated preventing state cells anti-PDX be by large pro-inflammatory macrophages. inhibitors; primary and First these cells These proportion or and suppress of cells VISTA T This derived sees enforcer acted anti-CTLA-X of upon a a sequester is T state second by quiescent T primary quiescent upon of the or MDS. a function promote acted a a actively checkpoint in effectiveness from
that we expression Finally, during know can anti-PDX anti-CTLA-X therapy. a compensatory dramatically treatment mechanism as increase with or VISTA
to therapeutic that to my later has and advanced to like shown of cancer crucial believe of in clinical will To utmost a a have this We deep therapy. believe of potential addition clinical and year. immune we forward extend progress CI-XXXX is and oncology development VISTA the arsenal targeting most currently changing a be teams, community the all up, initial reporting to appreciation reasons, these in has this entire the For antibody who game I'd look program, we therapy. already possible. to The the anti-VISTA wrap Curis excitement interest made data be this
help to eager over to targeted come quarter. that, call next in are the to efforts need. With our Bill? I'll patients financial the cancer and build to programs advance in We upon generation for the review our our turn quarters results Bill to
